Of these signaling molecules, EGFR, AKT, and STAT3 have been reported to participate in TGF-β-induced myofibroblast differentiation [40–42] and are being considered as potential therapeutic targets for IPF [27, 42–44]. The gene discussed is AKT1; the disease is idiopathic pulmonary fibrosis.